1
|
Wright DC, Adayapalam N, Bain N, Bain SM, Brown A, Buzzacott N, Carey L, Cross J, Dun K, Joy C, McCarthy C, Moore S, Murch AR, O'Malley F, Parker E, Watt J, Wilkin H, Fagan K, Pertile MD, Peters GB. Chromosome microarray proficiency testing and analysis of quality metric data trends through an external quality assessment program for Australasian laboratories. Pathology 2016; 48:586-96. [PMID: 27575971 DOI: 10.1016/j.pathol.2016.05.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 04/19/2016] [Accepted: 05/20/2016] [Indexed: 10/21/2022]
Abstract
Chromosome microarrays are an essential tool for investigation of copy number changes in children with congenital anomalies and intellectual deficit. Attempts to standardise microarray testing have focused on establishing technical and clinical quality criteria, however external quality assessment programs are still needed. We report on a microarray proficiency testing program for Australasian laboratories. Quality metrics evaluated included analytical accuracy, result interpretation, report completeness, and laboratory performance data: sample numbers, success and abnormality rate and reporting times. Between 2009 and 2014 nine samples were dispatched with variable results for analytical accuracy (30-100%), correct interpretation (32-96%), and report completeness (30-92%). Laboratory performance data (2007-2014) showed an overall mean success rate of 99.2% and abnormality rate of 23.6%. Reporting times decreased from >90 days to <30 days for normal results and from >102 days to <35 days for abnormal results. Data trends showed a positive correlation with improvement for all these quality metrics, however only 'report completeness' and reporting times reached statistical significance. Whether the overall improvement in laboratory performance was due to participation in this program, or from accumulated laboratory experience over time, is not clear. Either way, the outcome is likely to assist referring clinicians and improve patient care.
Collapse
Affiliation(s)
- D C Wright
- The Children's Hospital at Westmead, Westmead, NSW, Australia.
| | - N Adayapalam
- Royal Brisbane Hospital, Brisbane, Qld, Australia
| | - N Bain
- Hunter Area Pathology, Newcastle, NSW, Australia
| | - S M Bain
- SA Pathology, Adelaide, SA, Australia
| | - A Brown
- Wellington Hospital, Wellington, New Zealand
| | - N Buzzacott
- Western Genome Diagnostics, Perth, WA, Australia
| | - L Carey
- The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - J Cross
- The Children's Hospital at Westmead, Westmead, NSW, Australia
| | - K Dun
- Royal Hobart Hospital, Hobart, Tas, Australia
| | - C Joy
- Mater Hospital, Brisbane, Qld, Australia
| | - C McCarthy
- Queensland Fertility Group, Brisbane, Qld, Australia
| | - S Moore
- SA Pathology, Adelaide, SA, Australia
| | - A R Murch
- Retired, formerly at Pathwest Laboratory Medicine WA, QEII Medical Centre, Nedlands, WA, Australia
| | - F O'Malley
- St Vincents Hospital, Melbourne, Vic, Australia
| | - E Parker
- Canterbury Health Laboratories, Christchurch, New Zealand
| | - J Watt
- Canterbury Health Laboratories, Christchurch, New Zealand
| | - H Wilkin
- Monash Medical Centre, Melbourne, Vic, Australia
| | - K Fagan
- Retired, formerly at Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia
| | - M D Pertile
- Murdoch Children's Research Institute, Melbourne, Vic, Australia
| | - G B Peters
- The Children's Hospital at Westmead, Westmead, NSW, Australia
| |
Collapse
|
2
|
Cao Z, Yu R, Dun K, Burke J, Caplin N, Greenaway T. 22q11.2 deletion presenting with severe hypocalcaemia, seizure and basal ganglia calcification in an adult man. Intern Med J 2011; 41:63-6. [PMID: 21265963 DOI: 10.1111/j.1445-5994.2010.02374.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We report a 40-year-old man who was found to have profound hypocalcaemia and hypoparathyroidism when investigated for multiple, generalized, tonic/clonic seizures and a chest infection. Computed tomography scan of the brain revealed extensive symmetric bilateral calcification within the cerebellum, thalamus and basal ganglia. Molecular cytogenetic testing by fluorescent in situ hybridization using the commercial Vysis LSI DiGeorge/VCFS dual colour probe set showed a deletion of 22q11.2. The extraordinary feature of this case is the adult presentation of hypocalcaemia, hypoparathyroidism and basal ganglia calcification due to 22q11.2 deletion.
Collapse
Affiliation(s)
- Z Cao
- Departments of Diabetes and Endocrine Services General Medicine Radiology Cytogenetics Services Tasmanian Clinical Genetics Service, Royal Hobart Hospital, Hobart, Tasmania, Australia
| | | | | | | | | | | |
Collapse
|
3
|
Abstract
The number of Tasmanian devils in the wild is rapidly declining owing to a transmissible cancer, devil facial tumor disease (DFTD). Although progress has been made to understand the spread of this disease, crucial research on the pathogenesis of DFTD has been limited because of the threatened status of the host species. Here, the authors describe the development of a NOD/SCID (nonobese diabetic / severe combined immunodeficiency) mouse model that reproduces DFTD and provides a much-needed model to undertake studies into this intriguing transmissible cancer. Histologically, the DFTD produced in NOD/SCID mice (xenografted DFTD) was indistinguishable from the DFTD identified in Tasmanian devils. At the protein level, all xenografted DFTD tumors expressed periaxin, a marker that confirmed the diagnosis of DFTD. The karyotype of DFTD in NOD/SCID mice reproduced similar chromosomal alterations as seen in diseased devils. Furthermore, each NOD/SCID mouse inoculated with cultured DFTD tumor cells developed tumors, whereas DFTD did not develop in any of the inoculated immune-competent BALB/c mice.
Collapse
Affiliation(s)
- A. Kreiss
- Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia
| | - C. Tovar
- Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia
| | - D. L. Obendorf
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - K. Dun
- Royal Hobart Hospital, Department of Pathology, Cytogenetics Laboratory, Hobart, Tasmania, Australia
| | - G. M. Woods
- Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
4
|
Affiliation(s)
- N. D. Sargison
- Large Animal Practice; Royal (Dick) School of Veterinary Studies; Easter Bush Veterinary Centre; Roslin Midlothian EH25 9RG
| | - K. Dun
- Large Animal Practice; Royal (Dick) School of Veterinary Studies; Easter Bush Veterinary Centre; Roslin Midlothian EH25 9RG
| | - C. D. Penny
- Large Animal Practice; Royal (Dick) School of Veterinary Studies; Easter Bush Veterinary Centre; Roslin Midlothian EH25 9RG
| | - F. Howie
- SAC Veterinary Science Division; Bush Estate; Penicuik Midlothian EH26 OQE
| | - J. R. Thomson
- SAC Veterinary Science Division; Bush Estate; Penicuik Midlothian EH26 OQE
| |
Collapse
|